The present invention relates to a cell structure including cells containing at least hepatocytes and vascular endothelial cells, and extracellular matrix component, wherein the extracellular matrix components are disposed between the cells, and a liver sinusoidal network is provided between the cells.

Provided is a three-dimensional tissue, including: a first cellular region including cells of a first type; and a second cellular region including cells of a second type different from the first type, wherein the cells of the first type are cells that emit light by chemiluminescence, bioluminescence, or fluorescence in response to an external stimulus.

The present invention is directed to a mammalian-avian chimeric model system comprising a fertilized avian egg comprising a chorioallantoic membrane (CAM); and multiple types of mammalian cells dispersed in a hydrogel. Further provided is a method for preparing the system and a method of using the same.

A three-dimensional (3D) cell culture system comprising: a solid porous polymeric support, preferably comprising a biocompatible polymer; a first type of cells bound to the solid porous polymeric support; and a biocompatible hydrogel comprising a second type of cells, wherein biocompatible hydrogel is in physical contact with the solid porous polymeric support, is described. Methods for preparing this 3D cell culture system, as well as uses of this system for example for anticancer drug screening, are also described.

Provided is a 3D human liver organ model constructing method, comprising: preparing human primary liver cells, or mixed cells of same and liver non-parenchymal cells, or human liver cancer cell lines into a single cell suspension, and mixing the single cell suspension with a matrix material to obtain a mixed cell suspension; inoculating the mixed cell suspension into cultivation micropores of a 3D organ-on-a-chip, and carrying out cultivation at 37° C. to obtain a gelled 3D organ-on-a-chip; adding a culture medium into liquid storage holes of the organ-on-a-chip, and carrying out cultivation to obtain a 3D human liver organ model. Compared with other 2D human liver organ models, the constructed 3D human liver organ model has significantly enhanced response sensitivity to hepatotoxic drugs, and shows stronger hepatotoxic damage effect for reported hepatotoxic drugs. Compared with an animal model, the 3D human liver organ model can effectively eliminate the screening difference caused by species difference.

This disclosure generally describes comestible cell-based food products including a combination of cultured cells and dry cell powder and methods for preparing such cell-based food products. In one or more embodiments, the comestible cell-based food product comprises a mixture of cultured animal cells and dry cultured animal cell powder. For example, the comestible cell-based food product is produced by generating a homogenous mixture of cultured animal cells and dry cultured animal cell powder. In one or more embodiments, the dry cultured animal cell powder improves the texture of the resultant comestible cell-based food product by tailoring the hardness and/or adhesiveness of the comestible cell-based food product.

The invention provides an isolated dehydrated corneal tissue, comprising a full thickness corneal stroma, and substantially all, or all, of the Bowman's membrane, wherein the stroma contains cellular material. Also provided is a method to product the tissue and uses of the tissue.

Engineered tissue models based on three-dimensional (3D) scaffolds, also referred to herein as tissue-engineered 3D models, can be used as in vitro diagnostic and drug screening tools for predicting, preventing and/or treating cancer metastases.

Provided is a method for isolating a ureteric bud tip cell from cells, a tissue, or an organoid comprising the ureteric bud tip cell, comprising the following steps of contacting the cells, tissue, or organoid comprising the ureteric bud tip cell with a very low density lipoprotein receptor (VLDL-R) binding agent, and isolating the ureteric bud tip cell using the binding agent as an indicator.

The present disclosure relates to methods of preparing cell-based products for human consumption, in particular, from populations of such cell types as hepatocytes, adipocytes, myoblasts, and/or fibroblasts.